Compare VTSI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | INKT |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 45.2M |
| IPO Year | 1999 | 2021 |
| Metric | VTSI | INKT |
|---|---|---|
| Price | $3.76 | $10.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $35.00 |
| AVG Volume (30 Days) | 50.1K | ★ 174.6K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $185,971.00 | N/A |
| Revenue This Year | $28.39 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $189.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.55 | $6.66 |
| 52 Week High | $7.47 | $76.00 |
| Indicator | VTSI | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 52.93 |
| Support Level | N/A | $8.48 |
| Resistance Level | $4.68 | $12.97 |
| Average True Range (ATR) | 0.25 | 0.96 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 18.62 | 63.87 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.